D-1069-2019 Class III Terminated
FDA drug recall D-1069-2019 was initiated by Pfizer Inc. on Mar 15, 2019 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point The recall status is terminated (terminated Aug 11, 2022). Affected quantity: 500 cartons (25 vials per carton).
Recall details
- Product Type
- Drugs
- Report Date
- Apr 10, 2019
- Initiation Date
- Mar 15, 2019
- Termination Date
- Aug 11, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 500 cartons (25 vials per carton)
Product description
Cleocin Phosphate, clindamycin injection, USP, 900 mg/ 6 mL (150 mg/mL), 6 mL vial, Rx only, Distributed by Pharmacia & Upjohn Co, Division of Pfizer, Inc, New York, NY 10017. NDC 0009-3447-01
Reason for recall
Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point
Distribution pattern
Nationwide USA and Guam
Code information
Lot #: T78193, Exp.04/2019
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1069-2019
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026